IFNA1 and severe acute respiratory syndrome: GSEA analyses of the drug signatures showed that troglitazone increased the expression of genes classified as potential therapeutics for SARS (NES = 1.46, p-adj = 4.65 × 10−2), in addition to antiviral pathways such as the ISG15 and IFN-stimulated antiviral mechanisms.